欧盟药品监管机构本周未讨论百健(BIIB.US)与卫材(ESALY.US)旗下阿尔茨海默病药物Leqembi

智通财经网03-22

智通财经APP获悉，欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健(BIIB.US)及其日本合作伙伴卫材(ESALY.US)共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。不过，欧洲药品管理局周五公布的会议记录中并未有提及Leqembi的说明或建议。据悉，百健与卫材在1月向欧盟提交了Leqembi的上市许可申请。该申请是基于3期Clarity研究和...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2421818870?lang=zh_CN&edition=full","thumbnail":"https://img.zhitongcaijing.com/image/20240322/20240322203213_90972.png?x-oss-process=image/format,jpg/quality,Q_80","is_english":false,"pubTime":"2024-03-22 20:31","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2421818870","market":"sh","top_or_hot":-1,"title":"欧盟药品监管机构本周未讨论百健(BIIB.US)与卫材(ESALY.US)旗下阿尔茨海默病药物Leqembi","media":"智通财经网","content":"<div>\n<p>智通财经APP获悉，欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健(BIIB.US)及其日本合作伙伴卫材(ESALY.US)共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。不过，欧洲药品管理局周五公布的会议记录中并未有提及Leqembi的说明或建议。据悉，百健与卫材在1月向欧盟提交了Leqembi的上市许可申请。该申请是基于3期Clarity研究和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1090809.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>欧盟药品监管机构本周未讨论百健(BIIB.US)与卫材(ESALY.US)旗下阿尔茨海默病药物Leqembi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n欧盟药品监管机构本周未讨论百健(BIIB.US)与卫材(ESALY.US)旗下阿尔茨海默病药物Leqembi\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-22 20:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1090809.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健(BIIB.US)及其日本合作伙伴卫材(ESALY.US)共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。不过，欧洲药品管理局周五公布的会议记录中并未有提及Leqembi的说明或建议。据悉，百健与卫材在1月向欧盟提交了Leqembi的上市许可申请。该申请是基于3期Clarity研究和...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1090809.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1090809.html","article_id":"2421818870","we_media_id":null,"thumbnails":["https://img.zhitongcaijing.com/image/20240322/20240322203213_90972.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2421818870","pubTimestamp":1711110718,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健及其日本合作伙伴卫材共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4532":"文艺复兴科技持仓","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BIIB":"渤健公司","BK4139":"生物科技"},"translate_title":"The EU drug regulator did not discuss BIIB.US and Leqembi, an Alzheimer's disease drug owned by ESALY.US, this week","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"智通财经APP获悉，欧洲药品管理局此前曾表示，本周将举行口头听证会，以讨论百健(BIIB.US)及其日本合作伙伴卫材(ESALY.US)共同开发的阿尔茨海默病治疗药物Leqembi(通用名：lecanemab-irmb)。不过，欧洲药品管理局周五公布的会议记录中并未有提及Leqembi的说明或建议。据悉，百健与卫材在1月向欧盟提交了Leqembi的上市许可申请。该申请是基于3期Clarity研究和2b期临床研究的结果，表明Leqembi治疗可以减少早期阿尔茨海默病的临床衰退。卫材预计，欧盟委员会将在其2024财年第一季度(截至2024年6月30日)对Leqembi的上市许可申请做出决定。去年7月，美国食品药物监督管理局(FDA)宣布，该机构完全批准了Leqembi。Leqembi是第一款被证明可以减缓阿尔茨海默病进程的药物，这意味着这款年费用高达2.65万美元的药物将被广泛纳入美国医疗保险。2023年1月，FDA曾给予Leqembi“加速批准”许可，但并未被大规模纳入医保。值得注意的是，Leqembi无法治愈阿尔茨海默病。在卫材的临床试验中，该疗法在18个月内将早期阿尔茨海默病引起的认知能力下降减缓了27%。这种抗体药物每月两次通过静脉注射，针对一种与阿尔茨海默病相关的淀粉样蛋白。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2421818870"}